Cardiovascular MRI with ferumoxytol.
Cardiovascular MRI with ferumoxytol.
复制标题
DOI：
10.1016/j.crad.2016.03.020
复制
发表时间：
2016-08
影响因子：
2.6
通讯作者：
Hu, P.
中科院分区：
文献类型：
--
作者：
Finn, J. P.;Nguyen, K. -L.;Han, F.;Zhou, Z.;Salusky, I.;Ayad, I.;Hu, P.
对比增强磁共振血管成像(CEMRA)的实践在十年的跨度中发生了显著的变化。对那些肾功能严重受损的患者中与Gd相关的肾源性系统性纤维化的担忧促使低剂量CEMRA和非对比剂MRA的发展，以及寻找替代MR对比剂的努力。最初开发用于MRI的阿魏酸甘油(一种超小的超顺磁性氧化铁纳米颗粒)目前正获得美国(U.S.)的批准。美国食品药品监督管理局用于治疗成人肾脏疾病缺铁性贫血。自2009年临床应用以来，人们对阿魏酸甘油酯作为磁共振造影剂的科学和临床应用越来越感兴趣。阿魏酸甘油酯独特的物理化学和药代动力学特性，包括其长的血管内半衰期和高的R1弛豫度，支持了超出基于Gd的造影剂范围的一系列MRI应用。此外，尽管在生物系统中没有发现Gd，但铁是正常新陈代谢所必需的，营养性缺铁在全球范围内构成了重大的公共卫生挑战。一旦阿魏酸甘油酯的碳水化合物外壳被降解，其核心的元素铁就会被并入网状内皮系统。这些考虑将阿魏酸甘油酯定位为CEMRA和MRI领域潜在的游戏规则改变者。在这篇文章中，我们旨在总结我们在心血管应用阿魏酸甘油酯的经验，并简要介绍阿魏酸甘油酯增强磁共振应用的研究进展。
The practice of contrast enhanced magnetic resonance angiography (CEMRA) has changed significantly in the span of a decade. Concerns regarding gadolinium (Gd)-associated nephrogenic systemic fibrosis in those with severely impaired renal function spurred developments in low-dose CEMRA and non-contrast MRA as well as efforts to seek alternative MR contrast agents. Originally developed for MRI use, ferumoxytol (an ultra-small superparamagnetic iron oxide nanoparticle), is currently approved by the United States (U.S.) Food and Drug Administration for the treatment of iron deficiency anemia in adults with renal disease. Since its clinical availability in 2009, there has been rising interest in the scientific and clinical use of ferumoxytol as an MR contrast agent. The unique physicochemical and pharmacokinetic properties of ferumoxytol, including its long intravascular half-life and high r1 relaxivity, support a spectrum of MRI applications beyond the scope of Gd-based contrast agents. Moreover, whereas Gd is not found in biological systems, iron is essential for normal metabolism, and nutritional iron deficiency poses major public health challenges worldwide. Once the carbohydrate shell of ferumoxytol is degraded, the elemental iron at its core is incorporated into the reticuloendothelial system. These considerations position ferumoxytol as a potential game changer in the field of CEMRA and MRI. In this paper, we aim to summarize our experience on the cardiovascular applications of ferumoxytol and provide a brief synopsis of ongoing investigations on ferumoxytol-enhanced MR applications.
登录
查看更多内容
影响因子：
3.5
作者：
Florian, Anca;Ludwig, Anna;Yilmaz, Ali
通讯作者：
Yilmaz, Ali
影响因子：
7.5
作者：
Alam, Shirjel R.;Shah, Anoop S. V.;Semple, Scott I. K.
通讯作者：
Semple, Scott I. K.
影响因子：
6.1
作者：
Aregger, Fabienne;Wenaweser, Peter;Frey, Felix J.
通讯作者：
Frey, Felix J.
影响因子：
4.8
作者：
Barbash, Israel M.;Ben-Dor, Itsik;Waksman, Ron
通讯作者：
Waksman, Ron
DOI：
10.2215/cjn.03921106
发表时间：
2007-03-01
影响因子：
9.8
作者：
Deo, Aneet;Fogel, Mitchell;Cowper, Shawn E.
通讯作者：
Cowper, Shawn E.